Antiviral Drugs Market Projected to Reach $125.26 Billion by 2035

The global market for antiviral drugs was valued at $77.93 billion in 2025 and is projected to reach $125.26 billion by 2035, according to Credence Research. This represents a compound annual growth rate (CAGR) of 4.86% over the forecast period.

North America held the largest regional share in 2025 at 47.0%. The Asia Pacific region is anticipated to experience the fastest growth, with an estimated annual CAGR of 6.08%. The market encompasses drugs used to treat or prevent viral infections such as HIV, hepatitis, herpes, influenza, and COVID-19.

HIV medications constitute a significant portion of the market, accounting for 58.0% of indication revenue. Combination therapies make up 62.0% of revenue, as multi-agent regimens are dominant in HIV and Hepatitis C care.

Market growth is driven by the demand for long-term HIV therapies, increased hepatitis diagnosis, and the emergence of new long-acting prevention methods and streamlined treatment regimens. While generic medications enhance access to treatment, they typically generate lower revenue per treatment compared to newer formulations.